Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 15/20 | 0.79 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.79 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.79 |
| ▸ | TSHR | P16473 | 1/20 | 0.79 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.79 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.79 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.77 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11743993 | 0.91 | ADRB2 (0.79) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| Hydrochloric Acid SCHEMBL11744001 | 0.90 | TDP1 (0.80) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL6701896 | 0.90 | ADRB2 (0.77) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| Levosalbutamol SCHEMBL29361075 | 0.88 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| Albuterol SCHEMBL2489838 | 0.88 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| Albuterol SCHEMBL4913 | 0.88 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| (S)-Albuterol SCHEMBL29496690 | 0.88 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| Albuterol SCHEMBL121596 | 0.88 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| Albuterol SCHEMBL122805 | 0.88 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| Levosalbutamol SCHEMBL4003 | 0.88 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306162-A1 | Treatment of Inflammatory Disorders and Pain | SOSEI R&D LTD. (GB) | 2008-12-11 | — | — | US | claimed |
| US-20080306162-A1 | Treatment of Inflammatory Disorders and Pain | SOSEI R&D LTD. (GB) | 2008-12-11 | — | — | US | disclosed |
| EP-1896393-A1 | THE TREATMENT OF INFLAMMATORY DISORDERS AND PAIN | Sosei R&D Ltd. (GB) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007003896-A1 | THE TREATMENT OF INFLAMMATORY DISORDERS AND PAIN | SOSEI R & D LTD. (GB) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306162-A1 | Treatment of Inflammatory Disorders and Pain | HRH3, OPRL1, HRH2 | ADRB2 131/4885ADRB1 198/4885CYP1A2 2106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.